Electrophysiological Characterization of C9ORF72-Associated Amyotrophic Lateral Sclerosis: A Retrospective Study.


Journal

European neurology
ISSN: 1421-9913
Titre abrégé: Eur Neurol
Pays: Switzerland
ID NLM: 0150760

Informations de publication

Date de publication:
2019
Historique:
received: 18 06 2019
accepted: 04 01 2020
pubmed: 6 2 2020
medline: 23 6 2020
entrez: 5 2 2020
Statut: ppublish

Résumé

C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS). The aim of the present study was to determine whether C9ORF72-associated ALS (C9-ALS) patients present distinctive electrophysiological characteristics that could differentiate them from non C9ORF72-associated ALS (nonC9-ALS) patients. Clinical and electrodiagnostic data from C9-ALS patients and nonC9-ALS patients were collected retrospectively. For electroneuromyography, the mean values of motor conduction, myography, and the mean values of sensory conduction were considered. Furthermore, the proportion of ALS patients with electrophysiological sensory neuropathy was determined. No significant difference was observed between 31 C9-ALS patients and 22 nonC9-ALS patients for mean motor conduction and myography. For sensory conduction analyses, mean sensory conduction was not significantly different between both groups. In total, 38% of -C9-ALS patient and 21% of nonC9-ALS patients presented electrophysiological sensory neuropathy (p = 0.33). In -C9-ALS patients with electrophysiological sensory neuropathy, 80% (8/10) were male and 67% (6/9) presented spinal onset compare to 25% (4/16, p = 0.014) male and 25% (4/16, p = 0.087) with spinal onset in those without electrophysiological sensory neuropathy. Although not different from nonC9-ALS, these results suggest that sensory involvement is a frequent feature of C9-ALS patients, expanding the phenotype of the disease beyond the motor and cognitive domains.

Identifiants

pubmed: 32018264
pii: 000505777
doi: 10.1159/000505777
doi:

Substances chimiques

C9orf72 Protein 0
C9orf72 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-112

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Antoine Pegat (A)

ALS Center, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C et Service d'explorations Fonctionnelles Neurologiques, Bron, France, antoine.pegat@chu-lyon.fr.

Françoise Bouhour (F)

ALS Center, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C et Service d'explorations Fonctionnelles Neurologiques, Bron, France.

Kevin Mouzat (K)

Motoneuron Disease, Pathophysiology and Therapy, INM, University Montpellier, Service de Biochimie et Biologie Moléculaire, CHU Nîmes, Montpellier, Nîmes, France.

Christophe Vial (C)

ALS Center, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C et Service d'explorations Fonctionnelles Neurologiques, Bron, France.

Benoit Pegat (B)

Centre Hospitalier de Saint-Brieuc, Service de Neurologie, Saint-Brieuc, France.

Pascal Leblanc (P)

Institut NeuroMyoGène, Université Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Emmanuel Broussolle (E)

ALS Center, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C et Service d'explorations Fonctionnelles Neurologiques, Bron, France.
Faculté de Médecine Lyon Sud Charles Mérieux, Université Claude Bernard Lyon 1, Centre de Neurosciences Cognitives Marc Jeannerod, Lyon, France.

Stéphanie Millecamps (S)

Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France.

Serge Lumbroso (S)

Motoneuron Disease, Pathophysiology and Therapy, INM, University Montpellier, Service de Biochimie et Biologie Moléculaire, CHU Nîmes, Montpellier, Nîmes, France.

Emilien Bernard (E)

ALS Center, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C et Service d'explorations Fonctionnelles Neurologiques, Bron, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH